RLAY
RLAY
NASDAQ · Biotechnology

Relay Therapeutics Inc

$12.76
+0.25 (+2.00%)
As of May 9, 1:34 AM ET ·
Financial Highlights (FY 2026)
Revenue
16.81M
Net Income
-302,654,545
Gross Margin
Profit Margin
-1,800.6%
Rev Growth
+123.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.2% 61.2%
Operating Margin -1,971.6% -3,349.9% 34.0% 31.7%
Profit Margin -1,800.6% -3,206.0% 20.5% 21.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 16.81M 8.30M 220.69M 215.28M
Gross Profit 135.02M 131.71M
Operating Income -331,444,192 -277,933,692 75.10M 68.21M
Net Income -302,654,545 -252,156,044 45.13M 45.09M
Gross Margin 61.2% 61.2%
Operating Margin -1,971.6% -3,349.9% 34.0% 31.7%
Profit Margin -1,800.6% -3,206.0% 20.5% 21.0%
Rev Growth +123.3% +48.9% +11.7% +6.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 477.64M 487.30M
Total Equity 867.00M 902.73M
D/E Ratio 0.55 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -328,350,034 -289,236,526 96.01M 91.95M
Free Cash Flow 41.24M 69.53M